TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer
Status:
Recruiting
Trial end date:
2024-02-11
Target enrollment:
Participant gender:
Summary
This study was designed to evaluate the effectiveness and safety of TACE（transcatheter
arterial chemoembolization） combined with Apatinib and Camrelizumab for Hepatocellular
Carcinoma.
The primary outcome measure is to evaluate the objective response rate (ORR) of the therapy
for Hepatocellular Carcinoma.
The secondary Outcome measures include the duration of response (DOR), disease control rate
(DCR), progression-free survival rate (PFSR) [ Time Frame: 6- and 12-month], overall survival
rate (OSR) [ Time Frame: 6- and 12-month], the median progression-free survival time (mPFS)
and median overall survival time (mOS) of the therapy for Hepatocellular Carcinoma.
Moreover, this study aims to assess the safety and tolerability of the Therapy for
Hepatocellular Carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University